Cargando...
HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells
Histone deacetylase 6 (HDAC6)-selective inhibitors are potent anticancer agents that are gaining increasing attention and undergoing various developments. These have been approved or are under clinical trials for use with other anticancer agents, such as pomalidomide, anti-programmed death-ligand 1...
Gardado en:
| Publicado en: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7816281/ https://ncbi.nlm.nih.gov/pubmed/33574940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12462 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|